Pulse Biosciences
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Pulse Biosciences sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Pulse Biosciences: 10 sponsored US clinical trials, 2 recruiting.
Pulse Biosciences sponsors 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. The most-studied condition in this pipeline is Ablation, with 2 trials.
Top-decile sponsor footprint
Pulse Biosciences ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
10 total, page 1 of 1
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
NCT06959121
Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System
NCT07287176
CellFX Treat & Resect Low-Risk BCC Feasibility Study
NCT04918381
CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts
NCT04738734
Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions
NCT04539886
CellFX System for the Treatment of Cutaneous Non-Genital Warts
NCT04554394
Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study
NCT04249115
Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study
NCT04253418
Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
NCT03612570
Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study
NCT03846531
Therapeutic Areas
What is open in the Pulse Biosciences pipeline
2 recruiting of 10 indexed (20% open); 6 completed (60%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Ablation (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Pulse Biosciences: open-pipeline peers nationwide
Peers matched on 10 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Pulse Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 trials (± recruiting share)
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this Pulse Biosciences page
10 registered trials is a research-attention snapshot, not an endorsement of Pulse Biosciences or any single study.
- 2 of Pulse Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ablation is the condition Pulse Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ablation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Pulse Biosciences pipeline card: 10 registered trials from official public datasets.Report a data error.